Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-03-14 5:04 pm Purchase | 2022-03-10 | 13D | Cytek Biosciences, Inc. CTKB | RA CAPITAL MANAGEMENT L.P. | 13,139,327 9.800% | 2,057,164 (+18.56%) | Filing History |
| 2022-02-28 5:29 pm Purchase | 2022-02-28 | 13D | Cytek Biosciences, Inc. CTKB | RA CAPITAL MANAGEMENT L.P. | 11,082,163 8.300% | 1,475,135 (+15.35%) | Filing History |
| 2022-02-24 4:30 pm Purchase | 2022-02-14 | 13G | Vera Therapeutics, Inc. VERA | RA CAPITAL MANAGEMENT L.P. | 2,000,000 7.500% | 2,000,000 (New Position) | Filing History |
| 2022-02-18 4:36 pm Sale | 2021-12-31 | 13G | scPharmaceuticals Inc. SCPH | RA CAPITAL MANAGEMENT L.P. | 2,691,770 9.840% | -4,000,000 (-59.77%) | Filing History |
| 2022-02-14 4:11 pm Unchanged | 2021-12-31 | 13G | PhaseBio Pharmaceuticals, Inc. PHASQ | RA CAPITAL MANAGEMENT L.P. | 2,850,000 5.900% | 0 (Unchanged) | Filing History |
| 2022-02-14 4:11 pm Purchase | 2021-12-31 | 13G | Travere Therapeutics, Inc. TVTX | RA CAPITAL MANAGEMENT L.P. | 5,614,428 9.200% | 1,056,561 (+23.18%) | Filing History |
| 2022-02-14 4:11 pm Purchase | 2021-12-31 | 13G | scPharmaceuticals Inc. SCPH | RA CAPITAL MANAGEMENT L.P. | 6,691,770 9.840% | 3,172,772 (+90.16%) | Filing History |
| 2022-02-14 4:11 pm Sale | 2021-12-31 | 13G | Orchard Therapeutics plc ORTX | RA CAPITAL MANAGEMENT L.P. | 969,479 7.700% | -262,042 (-21.28%) | Filing History |
| 2022-02-14 4:11 pm Sale | 2021-12-31 | 13G | ChemoCentryx, Inc. CCXI | RA CAPITAL MANAGEMENT L.P. | 0 0.000% | -4,776,548 (Position Closed) | Filing History |
| 2022-02-14 4:11 pm Unchanged | 2021-12-31 | 13G | Kinnate Biopharma Inc. KNTE | RA CAPITAL MANAGEMENT L.P. | 3,593,052 8.200% | 0 (Unchanged) | Filing History |
| 2022-02-14 4:11 pm Purchase | 2021-12-31 | 13G | Pyxis Oncology, Inc. PYXS | RA CAPITAL MANAGEMENT L.P. | 2,282,173 7.000% | 367,239 (+19.18%) | Filing History |
| 2022-02-14 4:11 pm Purchase | 2021-12-31 | 13G | Xilio Therapeutics, Inc. XLO | RA CAPITAL MANAGEMENT L.P. | 2,002,217 7.300% | 469,450 (+30.63%) | Filing History |
| 2022-02-14 4:11 pm Purchase | 2021-12-31 | 13G | Rhythm Pharmaceuticals, Inc. RYTM | RA CAPITAL MANAGEMENT L.P. | 4,871,067 9.700% | 692,000 (+16.56%) | Filing History |
| 2022-02-14 4:11 pm Sale | 2021-12-31 | 13G | Atea Pharmaceuticals, Inc. AVIR | RA CAPITAL MANAGEMENT L.P. | 0 0.000% | -5,368,451 (Position Closed) | Filing History |
| 2022-02-14 4:11 pm Purchase | 2021-12-31 | 13G | Otonomy, Inc. OTIC | RA CAPITAL MANAGEMENT L.P. | 5,600,000 9.900% | 2,507,706 (+81.10%) | Filing History |
| 2022-02-14 4:11 pm Sale | 2021-12-31 | 13G | Seres Therapeutics, Inc. MCRB | RA CAPITAL MANAGEMENT L.P. | 0 0.000% | -235,110 (Position Closed) | Filing History |
| 2022-02-14 4:11 pm Purchase | 2021-12-31 | 13G | MacroGenics, Inc. MGNX | RA CAPITAL MANAGEMENT L.P. | 6,103,594 9.960% | 1,728,377 (+39.50%) | Filing History |
| 2022-02-14 4:11 pm Sale | 2021-12-31 | 13G | Phathom Pharmaceuticals, Inc. PHAT | RA CAPITAL MANAGEMENT L.P. | 3,115,008 9.900% | -710,000 (-18.56%) | Filing History |
| 2022-02-14 4:11 pm Purchase | 2021-12-31 | 13G | Ascendis Pharma A/S ASND | RA CAPITAL MANAGEMENT L.P. | 7,567,900 13.300% | 1,702,562 (+29.03%) | Filing History |
| 2022-02-14 4:11 pm Unchanged | 2021-12-31 | 13G | Olema Pharmaceuticals, Inc. OLMA | RA CAPITAL MANAGEMENT L.P. | 2,150,404 5.300% | 0 (Unchanged) | Filing History |